0016-3813
0016-3813
S0016-38132020000800001
10.24875/gmm.m20000392
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
México
00
00
2020
00
00
2020
156
1
49
[
2016
Sixth ed
]
[
2017
35
432-9
]
[
2014
123
3
3
305-7
]
[
2002
346
564-9
]
[
2018
78
10
10
2449-56
]
[
2016
6
10
10
e486
]
[
2011
365
474-5
]
[
2013
27
947-53
]
[
2016
175
661-7
]
[
2002
94
1532-7
]
[
2009
144
86-94
]
[
2017
92
814-29
]
[
2003
101
2496-506
]
[
2012
83
476-9
]
[
2016
91
585-9
]
[
2008
79
1255-7
]
[
1954
250
1
1
26-30
]
[
2016
3
4
4
e163-75
]
[
2003
30
2
2
]
[
1999
28
3
3
678-9
]
[
2003
30
2
2
110-5
]
[
1993
82
3148-50
]
[
South Thames Haematology Specialist Committee
2008
32
55-9
]
[
2016
66
443-59
]
[
2003
30
146-52
]
[
2000
52
497-9
]
[
2013
88
1
1
60-5
]
[
2018
29
Suppl 4
Suppl 4
iv41-50
]
[
2017
17
5
5
252-62
]
[
2011
470
7332
7332
115-9
]
[
2012
367
9
9
826-33
]
[
2011
11
1
1
85-7
]
[
2015
29
1
1
169-76
]
[
2014
28
166-73
]
[
2000
18
1
1
214-26
]
[
2009
113
4
4
]
[
2018
8
4
4
40
]
[
2005
16
1
1
132-8
]
[
2007
25
22
22
3344-9
]
[
2015
126
11
11
1392-4
]
[
2009
23
1
1
153-61
]
[
2009
113
16
16
3673-8
]
[
2013
381
9873
9873
1203-10
]
[
2010
85
9
9
670-4
]
[
1993
11
8
8
]
[
2002
3
3
3
163-6
]
[
2009
27
23
23
3830-5
]
[
2013
122
19
19
3276-82
]
[
2011
11
1
1
133-5
]
[
2003
78
21-33
]
[
2014
28
269-77
]
[
2018
11
11
11
863-79
]
[
2017
28
suppl 4
suppl 4
iv52-61
]
[
2016
91
7
7
719-34
]
[
2019
37
62-74
]
[
2012
119
4375-82
]
[
2007
138
176-85
]
[
2017
92
4
4
578-98
]
[
2017
1
1
508-17
]
[
2016
30
1005-17
]
[
2015
372
2
2
142-52
]
[
2016
375
14
14
1319
]
[
2016
375
8
8
754-66
]
[
2014
123
12
12
1826-32
]
[
2019
20
6
6
781-94
]
[
2015
126
20
20
2284-90
]
[
2017
130
8
8
974-81
]
[
2018
32
7
7
1567-74
]
[
2014
15
12
12
e538-48
]
[
2017
3
1
1
28-35
]
[
2014
28
269-77
]
[
Resumen Oncoguía Mieloma Múltiple 2017 - versión 3.1 [Internet]
]
[
2009
94
11
11
1599-602
]
[
2012
26
9
9
1986-2010
]
[
2017
31
10
10
2094-103
]
[
2016
17
8
8
e328-46
]
[
2019
2
1
1
e26
]
[
2019
54
204-11
]
[
2013
31
4529-35
]
[
2017
376
1311-20
]
[
2016
101
1398-406
]
[
2019
54
353-67
]
[
2019
37
14
14
1228-63
]
[
2019
9
44
]
[
2014
20
295-308
]
[
2016
111
178-86
]
[
2015
50
523-30
]
[
2019
25
2
2
248-55
]
[
2019
85
]
[
2017
7
5
5
250-9
]
[
2017
130
Supplement 1
Supplement 1
398
]
[
2017
130
399
]
[
2019
25
7
7
1312-9
]
[
2018
36
4
4
671-8
]
[
2014
93
1207-14
]
[
2011
114
600-7
]
[
2012
366
1770-81
]
[
2019
393
10168
10168
253-64
]
[
2013
30
3
3
234-46
]
[
2018
14
3
3
195-203
]
[
1967
18
2
2
158-62
]
[
2013
162
1
1
50-61
]
[
2013
31
2347-57
]
[
2006
91
968-71
]
[
2013
7th ed
]
[
2009
]
[
Nalbuphine [Internet]
]
[
]
[
2015
18
10
10
395-400
]
[
]
[
2018
16
41-6
]
[
2010
17
286-96
]
[
2015
9
2
2
289-4
]
[
2011
34
3
3
219-27
]
[
Fatigue Infoguide [Internet]
]
[
2000
29
4
4
237-40
]
[
NCCN: Clinical Practice Guidelines in Oncology
V.019
]
[
1997
]
[
1966
276
6
6
496
]
[
1984
]
[
2010
13
4
4
439-52
]
[
1985
98
2
2
310-57
]
[
2017
34
7
7
671-6
]
[
2010
24
6
6
559-64
]
[
2014
22
4
4
1131-41
]
[
2016
37
1
1
357-74
]
[
2019
34
280-7
]
[
2017
29
3
3
192-5
]
[
2016
92
1090
1090
466-70
]
[
2015
33
7
7
749-54
]
[
2008
21
2
2
201-5
]
[
2003
0
1
1
93-105
]
[
2014
]
[
2016
9
7
7
695-706
]
[
2016
140
Suppl 1
Suppl 1
S76-80
]
[
2016
22
2
2
248-55
]
[
2014
124
21
]
[
2018
183
538-56
]
[
National Practice Guidelines in Oncology (NCCN Guidelines)
V, 1.2020
]
[
2013
31
17
17
2189-204
]